Pathogenic bacteria rely on surface metal receptor proteins to acquire iron during infection
Ideal for human vaccine market
Ideal for animal vaccine market
Syntiron’s worldwide intellectual property includes over 90 issued patents and 50 pending applications covering a variety of Gram-negative and Gram-positive vaccine targets. Syntiron has the exclusive license to develop these technologies for human applications, while our sister company in the veterinary industry, Epitopix, develops the technology to improve animal health.
You can view issued United States patents by clicking the document below. For a complete portfolio of worldwide intellectual property, please contact us.
Syntiron actively seeks partnerships THAT Advance human vaccines. For more information on our project and partnership opportunities, please contact us.
1000 Westgate Drive
St Paul MN 55114